Table 1.

Baseline characteristics of hepatocellular carcinoma patients treated with sorafenib. The patients were distributed into two groups: one group with an increase in AOPP ≤0.2 μmol/L chloramine T equivalent between day 0 and day 15 (≤0.2 AOPP), and one group with ≥0.2 μmol/L chloramine T equivalent (≥0.2 AOPP)

AOPPd <0.2 groupAOPPd ≥0.2 group
Patients1016
Age, years, Average (SD)63.1 (15.9)65.6 (11.0)
Sex, Male/Female (%)80/2088/12
ECOG 0/1/≥ 2, (%)30/50/2044/50/6
Specific metastatic sites, n
Lung45
Liver1015
Other47
Duration of disease, months, Average (SD)11.2 (9.3)13.4 (11.9)
Cause of Cirrhosis, n
 Hepatitis C only45
 Hepatitis B only37
 Alcohol only21
 Other13
Child Pugh classification A/B/C, n8/2/011/5/0
MELD scorea10 (4–16)12 (6–19)
Weight (kg), Average (SD)66.8 (13.7.8)75.6 (9.8)
BMI, Average (SD)23.9 (5.8)25.5 (4.0)
Biologic Results
Albuminemia (g/dL)31.8 (22–36)37.7 (31–44)
Pre-albuminemia0.10 (0.05–0.18)0.18 (0.09–0.28)
Bilirubinemia31.0 (4–81)12.7 (4–22)
ALT80.9 (31–143)48 (15–127)
AST125.8 (24–418)77 (21–168)

aValues reported are median (25th percentile to 75th percentile).

  • Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group Criteria Performance Status; BMI, body mass index (weight/height2).